AAOS Clinical Practice Guideline Summary: Treatment of Metastatic Carcinoma and Myeloma of the Femur

被引:6
作者
Wodajo, Felasfa [1 ,2 ,3 ]
Colman, Matthew [1 ]
Getty, Patrick [1 ,4 ]
机构
[1] Rush Univ, Med Ctr, Richmond, IL 60612 USA
[2] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[3] Georgetown Univ, Washington, DC 20057 USA
[4] Univ Hosp, Case Comprehens Canc Ctr, Cleveland, OH USA
关键词
DIAGNOSED MULTIPLE-MYELOMA; ADVANCED BREAST-CANCER; ZOLEDRONIC ACID; BONE METASTASES; SKELETAL COMPLICATIONS; DOUBLE-BLIND; HIP-ARTHROPLASTY; PHASE-III; DENOSUMAB; FRACTURES;
D O I
10.5435/JAAOS-D-21-00888
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
The Musculoskeletal Tumor Society, in partnership with American Society of Clinical Oncology and American Society for Radiation Oncology, has developed a clinical practice guideline to assist providers with the care of patients with metastatic carcinoma and myeloma of the femur. The guideline was developed by an Expert Panel consisting of representatives of all three organizations by American Academy of Orthopaedic Surgeons (AAOS) methodologists using the AAOS standardized guideline development process. A systematic review of the available evidence was conducted, and the identified evidence was rated was rated for quality and potential for bias. Recommendations were developed based on this evidence in a standardized fashion. The guideline was approved by the guideline approval bodies of all three organizations. Thirteen recommendations were synthesized covering relevant subtopics such as imaging, use of bone-modifying agents, radiation therapy, and surgical reconstruction. The consensus of the expert panel was that bone-modifying agents may assist in reducing the incidence of femur fracture, regardless of tumor histology. The panel recommended the use of radiation therapy to decrease the rate of femur fractures for patients considered at increased risk. The panel recommended arthroplasty be considered to improve patient function and decrease the need of postoperative radiation therapy in patients with pathologic fractures in the femur.
引用
收藏
页码:E118 / E129
页数:12
相关论文
共 45 条
[2]   Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial [J].
Amadori, Dino ;
Aglietta, Massimo ;
Alessi, Barbara ;
Gianni, Lorenzo ;
Ibrahim, Toni ;
Farina, Gabriella ;
Gaion, Fernando ;
Bertoldo, Francesco ;
Santini, Daniele ;
Rondena, Roberta ;
Bogani, Paola ;
Ripamonti, Carla I. .
LANCET ONCOLOGY, 2013, 14 (07) :663-670
[3]   Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update [J].
Anderson, Kenneth ;
Ismaila, Nofisat ;
Flynn, Patrick J. ;
Halabi, Susan ;
Jagannath, Sundar ;
Ogaily, Mohammed S. ;
Omel, Jim ;
Raje, Noopur ;
Roodman, G. David ;
Yee, Gary C. ;
Kyle, Robert A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) :812-+
[4]   Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients [J].
Aviles, Agustin ;
Nambo, Maria-Jesus ;
Huerta-Guzman, Judith ;
Cleto, Sergio ;
Neri, Natividad .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (04) :207-210
[5]   A proposal for an atypical femur fracture treatment and prevention clinical practice guideline [J].
Dell, R. ;
Greene, D. .
OSTEOPOROSIS INTERNATIONAL, 2018, 29 (06) :1277-1283
[6]   Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates [J].
Fizazi, Karim ;
Lipton, Allan ;
Mariette, Xavier ;
Body, Jean-Jacques ;
Rahim, Yasmin ;
Gralow, Julie R. ;
Gao, Guozhi ;
Wu, Ling ;
Sohn, Winnie ;
Jun, Susie .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) :1564-1571
[7]   Clinical and functional comparison of endoprosthetic replacement with intramedullary nailing for treating proximal femur metastasis [J].
Gao, Hua ;
Liu, Zhenyu ;
Wang, Baojun ;
Guo, Ai .
CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) :209-214
[8]  
Herrenbruck T, 2002, CLIN ORTHOP RELAT R, P154
[9]   Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial [J].
Himelstein, Andrew L. ;
Foster, Jared C. ;
Khatcheressian, James L. ;
Roberts, John D. ;
Seisler, Drew K. ;
Novotny, Paul J. ;
Qin, Rui ;
Go, Ronald S. ;
Grubbs, Stephen S. ;
O'Connor, Tracey ;
Velasco, Mario R., Jr. ;
Weckstein, Douglas ;
O'Mara, Ann ;
Loprinzi, Charles L. ;
Shapiro, Charles L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01) :48-58
[10]   Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4Weeks inWomen With Breast Cancer Metastatic to Bone The OPTIMIZE-2 Randomized Clinical Trial [J].
Hortobagyi, Gabriel N. ;
Van Poznak, Catherine ;
Harker, W. Graydon ;
Gradishar, William J. ;
Chew, Helen ;
Dakhil, Shaker R. ;
Haley, Barbara B. ;
Sauter, Nicholas ;
Mohanlal, Ramon ;
Zheng, Ming ;
Lipton, Allan .
JAMA ONCOLOGY, 2017, 3 (07) :906-912